Our Services
Medical Information
Helpful Resources
Published on: 2/7/2026
Farxiga can help many seniors with heart failure and chronic kidney disease by reducing hospitalizations and cardiovascular death and by slowing kidney decline, even for those without diabetes. There are several factors to consider, including side effects, when to pause it during illness or surgery, and how kidney function, blood pressure, and hydration guide safe use, so see below for important details that could shape your next steps with your clinician.
Farxiga (dapagliflozin) is a prescription medication originally developed to help lower blood sugar in people with type 2 diabetes. Over the past several years, strong clinical evidence has shown that Farxiga also offers important heart and kidney benefits, even for people without diabetes. These benefits are especially meaningful for older adults, who are more likely to live with heart failure or chronic kidney disease.
Below is a clear, balanced look at how Farxiga works, why it may help seniors, what the benefits are for the heart and kidneys, and what risks should be considered.
Farxiga belongs to a class of medications called SGLT2 inhibitors. These drugs work by helping the kidneys remove excess glucose (sugar) and sodium through urine.
In simple terms, Farxiga:
This combination explains why Farxiga has become a key treatment not just for diabetes, but also for heart failure and chronic kidney disease (CKD).
As people age, the risks of:
all increase.
Farxiga is now widely used in older adults because it:
Clinical trials such as DAPA-HF and DAPA-CKD included many adults over age 65, showing benefits across age groups, including seniors.
Heart failure occurs when the heart cannot pump blood efficiently. This can lead to fatigue, shortness of breath, and fluid buildup. Farxiga has been shown to help in both major types of heart failure:
Studies show that Farxiga can:
These benefits occur whether or not a person has diabetes.
For older adults, avoiding hospital stays can:
Farxiga helps by gently reducing excess fluid and easing the workload on the heart.
Kidney function naturally declines with age. Conditions like diabetes, high blood pressure, and heart disease can speed this up.
Farxiga is now approved to help slow kidney disease progression in people with chronic kidney disease, including those without diabetes.
Farxiga:
For seniors, this can mean more years of stable kidney function.
Farxiga is generally started when kidney function (eGFR) is 25 or higher, depending on the condition being treated.
Because seniors may take multiple medications, doctors usually review:
before and after starting Farxiga.
Farxiga is well tolerated by many people, but no medication is risk-free.
These risks are uncommon, but seniors should be monitored closely—especially during illness, hot weather, or poor oral intake.
If symptoms like severe weakness, confusion, vomiting, or fainting occur, seek medical care immediately.
Because Farxiga increases urination, some people may notice:
In rare cases, these symptoms may overlap with a completely different condition that affects the body's ability to regulate water balance. If you're experiencing unexplained excessive thirst and urination that seems unusual or unrelated to your medication, you can use a free symptom checker for Diabetes Insipidus to explore whether your symptoms might be connected to this rare condition and help prepare questions for your doctor.
Farxiga may not be appropriate for everyone. Extra caution is needed if you:
Your doctor may temporarily stop Farxiga during acute illness or before surgery to reduce risk.
For many seniors, Farxiga offers meaningful protection for the heart and kidneys, helping reduce hospital stays and slow disease progression. Its benefits go beyond blood sugar control and extend to people with and without diabetes.
That said, individual health matters. Age, kidney function, other medications, and overall health all play a role in deciding if Farxiga is appropriate.
If you or a loved one is considering Farxiga—or already taking it—speak to a doctor about any symptoms, side effects, or concerns. This is especially important if anything feels serious or life-threatening. Open, ongoing communication with a healthcare professional is the safest way to get the full benefits while minimizing risks.
(References)
* Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Chaudhry GM, et al. Age and effect of dapagliflozin in heart failure with preserved ejection fraction in DELIVER trial. Eur Heart J. 2023 Mar 1;44(9):788-798.
* Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Claggett B, Greene SJ, et al. Efficacy and safety of dapagliflozin in older versus younger patients with chronic kidney disease: a prespecified subgroup analysis of the DAPA-CKD trial. Lancet Healthy Longev. 2023 Oct;4(10):e523-e532.
* Jhund PS, Abraham WT, Butler J, Desai AS, Filippatos G, Goyal P, et al. Efficacy and Safety of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Age: Insights From DAPA-HF. Circulation. 2022 May 31;145(22):1668-1681.
* Khazai NB, Williams K, Inman S, Kalayjian EJ, Kates M. SGLT2 inhibitors for heart failure and kidney disease: a focus on older adults. J Geriatr Cardiol. 2023 Apr 28;20(4):255-265.
* Baviera M, Manca P, De Luca M, Lapi F, Nardi R, Cammalleri V, et al. SGLT2 inhibitors in older adults: beyond glycaemic control. G Ital Cardiol (Rome). 2023 Aug;24(8):659-666.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.